en · de · es · fr · pt
methods-notes.peptides1126.com › Data › Peptide Identity And Structural Background — Complete Guide

Peptide Identity And Structural Background — Complete Guide

By Editorial Desk · published 2026-02-16 · last reviewed 2026-03-27 · Data

If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

Peptide Identity and Structural Background

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

Regulation, Literature and Verification

Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.

Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Synthetic cyclic heptapeptide
Molecular massApproximately 1024 g/molDepends on counter-ion content
AppearanceWhite to off-white powderCommonly supplied as a lyophilised solid
SolubilityFreely soluble in waterAlso dissolves in common aqueous buffers
Typical storage-20 degrees Celsius, desiccatedProtect from light and repeated freeze-thaw

Melanotan-2 Identity and Receptor Pharmacology

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Related pages on this site

Handling, Measurement, and Regulatory Context

Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.

Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.

Background and Receptor Mechanism

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Storage, Verification and Regulatory Status

Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.

Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.

Further detail

== Discovery == eIF4E was discovered as a cytoplasmic Messenger RNA cap binding protein functioning in translation by Filipowicz et al. In 1976. Two years later, in 1978, Sonenberg et al. confirmed Filipowicz et al.'s findings by repeating the same experiments and adding a crosslinking chemical to increase the stability of the mRNA-protein complex. This was the foundation for our understanding of eukaryotic cap-dependent translation initiation. These findings have been confirmed by numerous scientists and reviewed in many articles that confirmed eIF4E binds the mRNA cap to facilitate translation initiation in eukaryotes.

A study conducted in Canada reported that the levels of fecal acetic acid (but not butyric or propionic acid) were lower in 3 month old human infants who were predicted to have asthma by school age (based on a Phylogenetic Investigation of Communities by Reconstruction of Unobserved States prediction algorithm) compared to infants predicted not to do so. Finally, a study conducted in Japan found that the fecal levels of propionic but not acetic or butyric acid trended lower in 1 month old human infants that developed asthma by age 5 than in infants that did not develop asthma. The fecal levels of propionic as well acetic and butyric acid obtained from 1 week-, 1 year, and 5-year-old infants did not show this trend. The different SC-FA implicated in suppressing asthma in these three studies may reflect dietary or other differences between the populations of the three countries. In all events, the studies allow that, based on rodent studies, FFAR3 may mediate these SG-FA actions and, based on human studies, SC-FAs may act to suppress, or at least delay) the onset of, asthma in children. Further studies are needed to determine if FFAR3 is involved in the apparent actions of the cited SC-FAs in the development of asthma in children.

1561: Italian alchemist Isabella Cortese published her popular book The Secrets of Lady Isabella Cortese. The work included recipes for medicines, distilled oils and cosmetics, and was the only book published by a female alchemist in the 16th century. 1572: Italian botanist Loredana Marcello died from the plague – but not before developing several effective palliative formulas for plague sufferers, which were used by many physicians. 1572: Danish scientist Sophia Brahe (1556–1643) assisted her brother Tycho Brahe with his astronomical observations. 1590: After her husband's death, Caterina Vitale took over his position as chief pharmacist to the Order of St John, becoming the first female chemist and pharmacist in Malta.

=== Cancer === Preliminary studies suggest that FFAR2 may be involved in some types of cancer. 1) One study found that FFAR2 levels were elevated in human stomach and colorectal cancers although another study reported that FFAR2 levels were markedly deceased in human colorectal cancer. These results suggest that FFAR2 may promote the development and/or progression of human stomach cancer but its impact on human colorectal cancer requires further study. 2) In a dextran sulfate sodium-induced model of inflammation-associated colon cancer, FFAR2 knockdown mice developed larger and more tumors than control mice. This study suggests that FFAR2 inhibits the development and/or progression of inflammation-associated colon carcinoma in mice; its role in human inflammation-associated colorectal cancer (e.g., colorectal cancer developing in ulcerative colitis) has not been clarified. 3) Compared to their normal lung tissues, the lung cancer tissues of 42 patients had lower levels of FFAR2 but not FFAR1, FFAR3, or FFAR4. 4) Butyric acid inhibited the proliferation of and triggered apoptosis in cultured human A549 lung cancer cells; further studies in A549 as well as H1299 human lung cancer cells found that propionic acid inhibited their stimulated migration, invasiveness, and colony growth in cell culture assays but did not do so in FFAR2 gene knockout A549 or H1299 cells. These results suggest that FFAR2 may inhibit the development and/or progression of human lung cancer.

== Research == Anastrozole is surprisingly ineffective at treating gynecomastia, in contrast to selective estrogen receptor modulators like tamoxifen. Anastrozole was under development for the treatment of female infertility but did not complete development and hence was never approved for this indication. An anastrozole and levonorgestrel vaginal ring (developmental code name BAY 98–7196) was under development for use as a hormonal contraceptive and treatment for endometriosis. Development was discontinued in November 2018, and the formulation was never marketed. Anastrozole increases testosterone levels in males and has been studied as an alternative method of androgen replacement therapy in men with hypogonadism. However, there are concerns about its long-term influence on bone mineral density in this patient population, as well as other adverse effects.

Sources: en.wikipedia.org

Supporting material

The Francis Crick Institute "Francis Harry Compton Crick (1916–2004)" by A. Andrei at the Embryo Project Encyclopedia Francis Crick on Nobelprize.org Portraits of Francis Crick at the National Portrait Gallery, London Crick papers

== Side effects == Side effects of vosilasarm in preliminary clinical studies in women with metastatic breast cancer have included vomiting (27%), dehydration (27%), constipation, decreased appetite and weight loss (27%), hypophosphatemia, decreased sex hormone-binding globulin (SHBG) levels (100%), increased prostate-specific antigen (PSA) levels (80%), and abnormal liver function tests, including elevated aspartate aminotransferase (59%), elevated alanine aminotransferase (46%), and elevated total blood bilirubin (27%). In gonadally intact male cynomolgus monkeys, vosilasarm suppressed testosterone levels by around 50% (from ~600–800 ng/dL to ~200–300 ng/dL) across three dose levels (0.01 mg/kg, 0.1 mg/kg, and 1.0 mg/kg). Changes in serum lipids, including of triglycerides, LDL cholesterol, and HDL cholesterol were also observed. Elevated liver enzymes were minimally observed in monkeys. A number of case reports of liver toxicity with non-medical use of vosilasarm have been published. A case report of acute myocarditis with non-medical use of vosilasarm also exists.

To help the players develop the fictional history of Aperture Science, Valve created a digital comic to tell the story of the "Rat Man", a schizophrenic who is unseen in the games themselves but creates murals and scrawlings that guide Chell in both games. The comic, "Portal 2: Lab Rat", takes place both during and after Portal, explaining the events that led to Portal 2. The Rat Man's artwork appears early in Portal 2, where it retells the plot of Portal. Michael Avon Oeming, who had worked on comics for Valve games Team Fortress 2 and Left 4 Dead, and Valve in-house artist Andrea Wicklund drew the comic. Ted Kosmatka wrote most of the story with input from the Portal 2 writers. The 27-page comic was made available online in two parts about two weeks before the game's release and was also bundled with the game itself. Dark Horse Comics has published "Portal 2: Lab Rat" in a printed anthology of Valve comics, Valve Presents: The Sacrifice and Other Steam-Powered Stories, in November 2011. In the comic, Doug Rattmann (also known as The Rat Man) is a scientist working in the Aperture facility. He escapes GLaDOS's initial neurotoxin attack, but suffers symptoms as his schizophrenia medication runs out, causing hallucinations of his Weighted Companion Cube talking. Noticing that Chell is uniquely tenacious among the test subjects held by Aperture, Rattmann moves her to the top of the queue of testing subjects, thus starting the events of the first Portal.

Colin Edwards Interviews and Papers about Dylan Thomas, National Library of Wales "Papers of Colin Edwards (d. 1994), a radio journalist of Welsh descent, relating to his incomplete book on Dylan Thomas ('Dylan Remembered')" Dylan Thomas Collection at Harry Ransom Center University of Texas Dylan Thomas Digital Collection at Harry Ransom Center University of Texas & University of Swansea Dylan Thomas Digital Collection from the University at Buffalo Libraries "Archival material relating to Dylan Thomas". UK National Archives. Websites

Sources: en.wikipedia.org

Supporting material

In 2013, researchers demonstrated graphene's high mobility in a detector that allows broad band frequency selectivity ranging from the THz to IR region (0.76–33 THz) A separate group created a terahertz-speed transistor with bistable characteristics, which means that the device can spontaneously switch between two electronic states. The device consists of two layers of graphene separated by an insulating layer of boron nitride a few atomic layers thick. Electrons move through this barrier by quantum tunneling. These new transistors exhibit negative differential conductance, whereby the same electric current flows at two different applied voltages. In June, an 8 transistor 1.28 GHz ring oscillator circuit was described. The negative differential resistance experimentally observed in graphene field-effect transistors of conventional design allows for construction of viable non-Boolean computational architectures. The negative differential resistance—observed under certain biasing schemes—is an intrinsic property of graphene resulting from its symmetric band structure. The results present a conceptual change in graphene research and indicate an alternative route for graphene applications in information processing. In 2013 researchers created transistors printed on flexible plastic that operate at 25 gigahertz, sufficient for communications circuits and that can be fabricated at scale. The researchers first fabricated non-graphene-containing structures—the electrodes and gates—on plastic sheets.

== Standardization == The phenomenon of standardization is "a concept used to characterize the formulaic products of capitalist-driven mass media and mass culture that appeal to the lowest common denominator in pursuit of maximum profit." According to Adorno, we inhabit a media-culture-driven society that has product consumption as one of its main characteristics. Mass media is employed to deliver messages about products and services to consumers in order to convince these individuals to purchase the commodity they are advertising. Standardization consists of the production of large amounts of commodities to then pursue consumers in order to gain the maximum profit possible. They do this by individualizing products to give the illusion to consumers that they are in fact purchasing a product or service that was specifically designed for them. Adorno highlights the issues created with the construction of popular music, where different samples of music used in the creation of today's chart-topping songs are put together in order to create, recreate, and modify numerous tracks by using the same variety of samples from one song to another. He makes a distinction between "Apologetic music" and "Critical music." Apologetic music is defined as the highly produced and promoted music of the "pop music" industry: music that is composed of variable parts and interchanged to create several different songs.

==== Vitamin C ==== Ascorbic acid or vitamin C, an oxidation-reduction (redox) catalyst found in both animals and plants, can reduce, and thereby neutralize, ROS, such as hydrogen peroxide. In addition to its direct antioxidant effects, ascorbic acid is also a substrate for the redox enzyme ascorbate peroxidase, a function that is used in stress resistance in plants. Ascorbic acid is present at high levels in all parts of plants and can reach concentrations of 20 millimolar in chloroplasts.

Sources: en.wikipedia.org

Frequently asked questions

What is Melanotan-2 chemically?

It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.

How does it differ from the natural hormone?

It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.

When was Melanotan-2 first described?

Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.

Has it been tested in clinical trials?

Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.

Network